Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive... BRIEF REPORT Development of Renal Cysts after Crizotinib Treatment in  Advanced ALK-Positive Non–Small-Cell Lung Cancer Yen-Ting Lin, MD,* Yu-Fen Wang, MD,† James Chih-Hsin Yang, MD, PhD,‡ Chong-Jen Yu, MD, PhD,§ Shang-Gin Wu, MD,* Jin-Yuan Shih, MD, PhD,§ and Pan-Chyr Yang, MD, PhD,§ rizotinib is an inhibitor of several receptor tyrosine Introduction: The development of complex renal cysts after crizo- Ckinases, including anaplastic lymphoma kinase (ALK), tinib treatment for non–small-cell lung cancer (NSCLC) is a reported hepatocyte growth factor receptor (HGFR, c-Met), and side effect. However, its occurrence and characteristics have not been c-ros oncogene 1. It has been approved for the treatment of reported. advanced ALK-positive non–small-cell lung cancer (NSCLC) Methods: Medical records and computed tomography images of in many countries. The development of complex renal cyst crizotinib-treated patients in three prospective clinical trials were has been observed in seven (4%) patients as stated in the lat- reviewed. The size and Bosniak category of the renal cysts before est label of crizotinib published by the US Food and Drug and after crizotinib treatment were determined. Patients’ clinical Administration (FDA). However, its occurrence and charac- characteristics, tumor stage, treatment response, renal function, and teristics have not been reported. outcomes were analyzed. Renal cysts are common radiologic findings. Bosniak Results: During December http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer

Yang, Pan-Chyr
Journal of Thoracic Oncology , Volume 9 (11) – Nov 1, 2014
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/development-of-renal-cysts-after-crizotinib-treatment-in-advanced-alk-gZC7Y0RPum

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000326
pmid
25436806
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Development of Renal Cysts after Crizotinib Treatment in  Advanced ALK-Positive Non–Small-Cell Lung Cancer Yen-Ting Lin, MD,* Yu-Fen Wang, MD,† James Chih-Hsin Yang, MD, PhD,‡ Chong-Jen Yu, MD, PhD,§ Shang-Gin Wu, MD,* Jin-Yuan Shih, MD, PhD,§ and Pan-Chyr Yang, MD, PhD,§ rizotinib is an inhibitor of several receptor tyrosine Introduction: The development of complex renal cysts after crizo- Ckinases, including anaplastic lymphoma kinase (ALK), tinib treatment for non–small-cell lung cancer (NSCLC) is a reported hepatocyte growth factor receptor (HGFR, c-Met), and side effect. However, its occurrence and characteristics have not been c-ros oncogene 1. It has been approved for the treatment of reported. advanced ALK-positive non–small-cell lung cancer (NSCLC) Methods: Medical records and computed tomography images of in many countries. The development of complex renal cyst crizotinib-treated patients in three prospective clinical trials were has been observed in seven (4%) patients as stated in the lat- reviewed. The size and Bosniak category of the renal cysts before est label of crizotinib published by the US Food and Drug and after crizotinib treatment were determined. Patients’ clinical Administration (FDA). However, its occurrence and charac- characteristics, tumor stage, treatment response, renal function, and teristics have not been reported. outcomes were analyzed. Renal cysts are common radiologic findings. Bosniak Results: During December

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2014

References

  • Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
    Ou
  • ROS1 rearrangements define a unique molecular class of lung cancers
    Bergethon